SEARCH

SEARCH BY CITATION

References

  • Allan, N.C., Richards, S.M. & Shepherd, P.C. (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet, 345, 13921397.
  • Bauermeister, D.E. (1971) Quantitation of bone marrow reticulin - a normal range. American Journal of Clinical Pathology, 56, 2431.
  • Buhr, T., Georgii, A. & Choritz, H. (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathology, Research and Practice, 189, 121132.
  • Cervantes, F. & Rozman, C. (1982) A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood, 60, 12981304.
  • Cervantes, F., Rozman, C. & Feliu, E. (1989) Prognostic evaluation of initial bone marrow histopathological features in chronic granulocytic leukemia. Acta Haematologica, 82, 1215.
  • Cox, D.R. (1972) Regression models and life-tables (with discussion). Journal of the Royal Statistical Society Series B, 34, 187220.
  • Dekmezian, R., Kantarjian, H.M., Keating, M.J., Talpaz, M., McCredie, K.B. & Freireich, E.J. (1987) The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer, 59, 17391743.
  • Eaves, A.C., Henkelman, D.H. & Eaves, C.J. (1980) Abnormal erythropoiesis in the myeloproliferative disorders: an analysis of underlying cellular and humoral mechanisms. Experimental Hematology, 8, 235247.
  • Facchetti, F., Tironi, A., Marocolo, D., Capucci, A., Ruggeri, G., Bellotti, D. & Rossi, G. (1997) Histopathological changes in bone marrow biopsies from patients with chronic myeloid leukaemia after treatment with recombinant alpha-interferon. Histopathology, 31, 311.
  • Georgii, A., Vykoupil, K.F., Buhr, T., Choritz, H., Dohler, U., Kaloutsi, V. & Werner, M. (1990) Chronic myeloproliferative disorders in bone marrow biopsies. Pathology, Research and Practice, 186, 327.
  • Hasford, J., Ansari, H., Pfirrmann, M. & Hehlmann, R. (1996) Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplantation, 17, S49S54.
  • Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N.C., Baccarani, M., Kluin-Nelemans, J.C., Alimena, G., Steegmann, J.L. & Ansari, H. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute, 90, 850858.DOI: 10.1093/jnci/90.11.850
  • Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Loffler, H., Hochhaus, A. & Heinze, B., (1994) Randomized comparison of interferon-alpha with busulphan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 84, 40644077.
  • Hehlmann, R., Heimpel, H., Hossfeld, D.K., Hasford, J., Kolb, H.J., Loffler, H., Pralle, H., Queisser, W., Hochhaus, A., Tichelli, A., Fett, W., Schmitz, N., Reiter, A., Griesshammer, M., Pfeifer, W., Bumler, M., Kamp, T., Tobler, A., Eimermacher, H., Kuse, R., Berger, U. & Ansari, H. (1996) Randomized study of the combination of hydroxyurea and interferon alpha vs. hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. Bone Marrow Transplantation, 17, S21S24.
  • Hehlmann, R., Ansari, H., Hasford, J., Heimpel, H., Hossfeld, D.K., Kolb, H.J., Loffler, H., Pralle, H., Queisser, W., Reiter, A. & Hochhaus, A. (1997a) Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML) -Study Group. British Journal of Haematology, 97, 7685.
  • Hehlmann, R., Willer, A., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Loffler, H., Hochhaus, A., Tobler, A., Lengfelder, E., Berger, U. & Leib-Mosch, C. (1997b) Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group. Leukemia, 11, 506511.
  • Kalbfleisch, J. & Prentice, R. (1980). The Statistical Analysis of Failure Time Data. Wiley, New York.
  • Kantarjian, H.M., Smith, T.L., McCredie, K.B., Keating, M.J., Walters, R.S., Talpaz, M., Hester, J.P., Bligham, G., Gehan, E. & Freireich, E.J. (1985) Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood, 66, 13261335.
  • Kantarjian, H.M., Keating, M.J., Smith, T.L., Talpaz, M. & McCredie, K.B. (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. American Journal of Medicine, 88, 18.
  • Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S. & Talpaz, M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Annals of Internal Medicine, 122, 254261.
  • Kloke, O., Niederle, N., Opalka, B., Hawig, I., Seeber, S. & Becher, R. (1996) Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up. European Journal of Haematology, 56, 7881.
  • Lazzarino, M., Morra, E., Castello, A., Inverardi, D., Coci, A., Pagnucco, G., Magrini, U., Zei, G. & Bernasconi, C. (1986) Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. British Journal of Haematology, 64, 227240.
  • Levis, A., Marmont, F., Ciocca Vasino, M.A., Jayme, A., Infelise, V., Cametti, G., Canta, M. & Resegotti, L. (1986) Peripheral erythroid precursor and prognosis in chronic granulocytic leukemia. Cancer, 58, 229233.
  • Ohnishi, K., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S., Tsubaki, K., Miura, Y., Omine, M., Kobayashi, T., Naoe, T., Ohshima, T., Hirashima, K., Ohtake, S., Takahashi, I., Morishima, Y., Naito, K., Asou, N., Tanimoto, M., Sakuma, A. & Ohno, R. (1998) A long term follow-up of a randomized trial comparing interferon-alpha with busulphan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leukemia Research, 22, 779786.DOI: 10.1016/s0145-2126(98)00082-4
  • Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer, 35, 139.
  • Rajantie, J., Sale, G.E., Deeg, H.J., Amos, D., Appelbaum, F., Storb, R., Clift, R.A. & Buckner, C.D. (1986) Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood, 67, 16931697.
  • Ross, D.W., Brunning, R.D., Kantarjian, H.M., Koeffler, H.P. & Ozer, H. (1993) A proposed staging system for chronic myeloid leukemia. Cancer, 71, 37883791.
  • Rozman, C., Cervantes, F. & Feliu, E. (1989) Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view? European Journal of Haematology, 42, 150154.
  • Sacchi, S. (1995) The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leukemia and Lymphoma, 19, 1320.
  • Schaefer, H. (1984) How to fix, decalcify and stain paraffin embedded bone marrow biopsies. In: Pathology of the Bone Marrow, (ed. by K.Lennert & K. Hübner), pp. 69. Fischer, Stuttgart.
  • Silver, R.T., Woolf, S.H., Hehlmann, R., Appelbaum, F.R., Anderson, J., Bennett, C., Goldman, J.M., Guilhot, F., Kantarjian, H.M., Lichtin, A.E., Talpaz, M. & Tura, S. (1999) An evidence-based analysis of the effect of busulphan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 94, 15171536.
  • Sokal, J.E., Cox, E.B., Baccarani, M., Tura, S., Gomez, G.A., Robertson, J.E., Tso, C.Y., Braun, T.J., Clarkson, B.D. & Cervantes, F. (1984) Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood, 63, 789799.
  • Straetmans, N., Ma, D.D., Nevell, D.F. & Arthur, C. (1996) Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy. Hematopathology and Molecular Hematology, 10, 213222.
  • Thaler, J., Gastl, G., Fluckinger, T., Niederwieser, D., Huber, H., Seewann, H., Sill, H., Lang, A., Falk, M., Duba, C., Utermann, G., Kuhr, T., Aulitzky, W. & Huber, C. (1996) Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group. Annals of Hematology, 72, 349355.DOI: 10.1007/s002770050185
  • The Benelux CML Study Group (1998) Randomized study on hydroxyurea alone vs. hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood, 91, 27132721.
  • The Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1988) Prospective confirmation of a prognostic classification for Ph+ chronic myeloid leukaemia. British Journal of Haematology, 69, 463466.
  • The Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1991) Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. Annals of Hematology, 63, 307314.
  • The Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1993) Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. Leukemia and Lymphoma, 11, 6771.
  • The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820825.
  • Thiele, J., Kvasnicka, H.M., Titius, B.R., Parpert, U., Nebel, R., Zankovich, R., Dienemann, D., Stein, H., Diehl, V. & Fischer, R. (1993a) Histological features of prognostic significance in CML-an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Annals of Hematology, 66, 291302.
  • Thiele, J., Hoefer, M., Kvasnicka, H.M., Bertsch, H.P., Zankovich, R. & Fischer, R. (1993b) Erythropoiesis in CML – immunomorphometric quantification, PCNA-reactivity, and influence on survival. Hematologic Pathology, 7, 239249.
  • Thiele, J., Kvasnicka, H.M., Schmitt-Graeff, A., Zirbes, T.K., Birnbaum, F., Kressmann, C., Melguizo-Grahmann, M., Frackenpohl, H., Sprungmann, C., Leder, L.D., Diehl, V., Zankovich, R., Schaefer, H.E., Niederle, N. & Fischer, R. (2000) Bone marrow features and clinical findings in chronic myeloid leukemia – a comparative, multicenter, immunohistological and morphometric study on 614 patients. Leukemia and Lymphoma, 36, 295308.
  • Wilhelm, M., Bueso-Ramos, C., O'Brien, S., Pierce, S., Keating, M., Talpaz, M. & Kantarjian, H.M. (1998) Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia, 12, 6570.